Canagliflozin review - safety and efficacy profile in patients with T2DM

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Haroon JakherKenneth W Mahaffey

Abstract

Canagliflozin is a sodium glucose-cotransporter (SGLT) receptor inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). This article reviews the mechanism of action of SGLT-2 receptor inhibitors and the efficacy of canagliflozin as an antidiabetic agent, its cardiovascular and renal benefits, and safety profile. During the development of canagliflozin, Phase II trials showed an improvement in cardiac and renal biomarkers such as blood pressure, body weight, and albuminuria. The large CANVAS program showed that canagliflozin reduced the composite cardiovascular outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The CANVAS program also showed a possible benefit of canagliflozin on a renal composite of sustained 40% reduction in estimated glomerular filtration rate, the need for renal replacement therapy, or death from renal causes. The safety profile of canagliflozin has been well characterized, and known side effects such as mycotic genital infections were confirmed in CANVAS. However, an increased risk of amputations was observed in CANVAS that requires further study. Overall, canagliflozin is an effective antidiabetic medication with cardiovascular and likely renal benefits, a...Continue Reading

Citations

Aug 5, 2020·Future Cardiology·Ashish SarrajuKenneth W Mahaffey
Jul 30, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Miguel ValdésElizabeth Barbosa
Oct 8, 2020·Nucleic Acid Therapeutics·Suxiang ChenRakesh N Veedu
Feb 5, 2021·Future Cardiology·Vivencio Barrios, Carlos Escobar
Jul 31, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Mohamed A MorsyYasmine F Ibrahim
Sep 4, 2021·Journal of Pharmaceutical and Biomedical Analysis·Filip VymyslickýEwa Bartosińska

❮ Previous
Next ❯

Methods Mentioned

BETA
amputations
amputation

Clinical Trials Mentioned

NCT02173275
NCT01730534
NCT03594110
NCT03036150
NCT01986881

Software Mentioned

R
VERTIS
CREDENCE
CANTATA
CANVAS

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.